ZYME: Zymeworks Inc.
Performance
ZYME +87.18%
Watchlist
Select an item
Summary
ZYME at a glance
ZYME returned +87.18% over the past year and +5.91% a year over five years. Its worst drop in that year was -23.63%, smaller than 72% of stocks on Redstone, and its Sharpe ratio of 1.35 beats 88% of stocks on Redstone. It pays no dividends.
Current Drawdown
-0.77%
Rolling Volatility
45.42%
Actions
Metrics
Risk Indicators
Alpha64.25%
Beta0.93x
Sharpe1.35
Sortino2.40
Omega1.27
Calmar3.69
Martin5.84
Profile
About ZYME
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $2.2B
- Listed
- Apr 2017
- Employees
- 264
- Headquarters
- Middletown, DE
- Website
- zymeworks.com
Comparisons